About
Small Molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Team (8)
Anthony Ford
Anthony Ford, PhD
CuraSen Therapeutics
team_member
Gabriel Vargas
Gabriel Vargas, MD, PhD
CuraSen Therapeutics
team_member
Kathleen Sereda Glaub
Kathleen Sereda Glaub, MBA
CuraSen Therapeutics
team_member
Mehrdad Shamloo
Mehrdad Shamloo, PhD
CuraSen Therapeutics
team_member
Michael P
Michael P. Dillon, PhD
CuraSen Therapeutics
team_member
Peter Butera
Peter Butera
CuraSen Therapeutics
team_member
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
117
By Phase
PHASE2: 4PHASE1: 1
By Status
WITHDRAWN: 2COMPLETED: 2RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT07089043Lead Sponsor
A Study in Subjects With Neurogenic Orthostatic Hypotension
PHASE2Recruiting
12 participants
Started: Sep 12, 2025 · Completed: Dec 31, 2025
NCT04935762Lead Sponsor
A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)
PHASE2Withdrawn
Started: Jun 30, 2024 · Completed: Mar 31, 2025
NCT05104463Lead Sponsor
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
PHASE2Completed
64 participants
Started: Apr 11, 2022 · Completed: Feb 1, 2024
NCT05033912Lead Sponsor
A Study of CST-2032 in Subjects With Cognitive Impairment
PHASE1Withdrawn
Started: Oct 31, 2021 · Completed: May 31, 2022
NCT04739423Lead Sponsor
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
PHASE2Completed
41 participants
Started: Jun 28, 2021 · Completed: Aug 31, 2022
Locations (1)
Headquarters
San Carlos, CA, United States
Map
Loading map...